Pfizer's 14% operational growth in non-COVID products shows the core business is stronger than many believe. The company's ...

Pfizer Inc. Chief Executive Officer Albert Bourla said he’ll do “whatever it takes” to keep profits growing, including ...

Pfizer's earnings were better than investors and management had anticipated. Its financial projections and forecasting abilities recently came under fire. It also raised its annual guidance, which ...

With the total return of Pfizer's (NYSE: PFE) shares rising by just 1.9% this year so far, investors may be yearning for some ...

Pfizer's quarterly earnings handily beat expectations, a boost for the company as it faces pressure from an activist investor ...

A boost from COVID-19 treatment sales helped bush Pfizer to a better-than-expected third quarter and higher forecast for the ...

Pfizer ( PFE) raised its full-year guidance by $1.5 billion and posted strong third quarter earnings Tuesday. The company now ...

Company CEO Albert Bourla said Pfizer would consider “any good ideas” that create value, but argued it has already made ...

Pfizer had a "constructive" meeting with activist investor Starboard Value last week and spoke publicly about it for the ...

Truist Financial analyst Srikripa Devarakonda maintained a Buy rating on Pfizer (PFE – Research Report) today. The company’s shares ...

Pfizer has a well-diversified pipeline, with several late-stage assets to drive medium-term growth. Learn more about PFE ...

In August, the Food and Drug Administration authorized updated vaccines against COVID-19. Here's what to know about the three ...